Do GLP-1s Cause Muscle Loss? What the Evidence Says (and How to Protect Lean Mass)

GLP-1 treatment can reduce lean mass as weight falls, but lean mass is not the same measurement as skeletal muscle. The proportion varies substantially across studies³. Changes in strength and mobility matter alongside the scan result when planning nutrition and exercise^3,5.

The finding that set off the alarm

In the STEP-1 body-composition substudy, adults on semaglutide lost more fat mass than lean mass. The proportion of their body that was lean tissue increased because fat fell faster than lean¹. A smaller measured amount of lean tissue can therefore occur alongside an improvement in overall body composition; it does not by itself show a loss of strength or function.

How much lean mass is lost?

The cited review reports substantial variation: some studies found lean mass accounted for approximately 15% or less of total weight lost, while others reported 40% to 60%. Lean-mass measures can include muscle alongside organs, bone and fluids, so a change in lean mass is not a direct measurement of skeletal-muscle loss³. Semaglutide and tirzepatide can produce substantial total weight loss — about 15% average in STEP-1 and up to roughly 21% in SURMOUNT-1⁴ — making body composition worth discussing. But a hypothetical 40-pound loss with a third classified as lean mass would not mean that all of that third was muscle.

Why it happens

Reduced appetite can make it harder to eat enough during treatment. Nutrition, activity, the amount of weight lost and a person's health can all matter when interpreting body-composition changes². The cited studies do not quantify how much lean-mass loss an individual can prevent.

Is it actually a problem?

Lean-mass change alone does not show whether muscle health has deteriorated. Strength, mobility, baseline muscle health and medical conditions also matter, particularly for older adults or people at risk of sarcopenia². Discuss changes in function with your clinician rather than interpreting a body-composition percentage as a diagnosis.

Nutrition when appetite falls

Ask your clinician or dietitian whether your reduced appetite is making it difficult to meet your nutritional needs. Protein intake should be individualized, including for kidney health and other medical conditions^2,3.

What the exercise evidence can tell you

A randomized trial in dieting older adults found that exercise type affected lean-mass preservation and physical function during weight loss⁵. That study did not test a GLP-1 medication, so it cannot quantify how much muscle a particular exercise plan will preserve during GLP-1 treatment. Reviews discuss exercise among approaches to supporting muscle health³. Ask your clinician what activity is appropriate for your health and current ability.

Does the drug or the dose matter?

Differences in study populations and how body composition is measured limit comparisons between medicines and dosing approaches³. These results do not establish a universal muscle-preserving advantage for one medicine or titration schedule. Medication and dose decisions also need to account for your symptoms, nutritional intake and function. Our semaglutide vs. tirzepatide comparison covers weight-loss results, tolerability and cost.

How to interpret your results

A body-composition percentage is one part of the picture. If getting out of a chair, carrying groceries or other everyday activities becomes harder, tell your clinician rather than relying on the scan alone. An assessment of nutrition, activity and physical function can put the measurement in context. Related reading covers facial fat loss and hair shedding during weight loss.

If you're choosing a provider, ask how its clinical team handles difficulty eating, questions about nutrition and changes in physical function. The 2-minute quiz compares providers using support level, medication and budget; it does not predict muscle outcomes. The cost calculator helps compare published pricing.